Cohort B: PD-L1 TPS≥ 1% for Advanced Non Small Cell Lung Cancer (NSCLC)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Advanced Non Small Cell Lung Cancer (NSCLC)+2 More
Adagrasib in combination with pembrolizumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

Study 849-017 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of combination therapies with adagrasib in patients with advanced NSCLC with TPS ≥ 1% and KRAS G12C mutation

Eligible Conditions
  • Advanced Non Small Cell Lung Cancer (NSCLC)
  • Metastatic Lung Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 4 Secondary · Reporting Duration: 30 months

30 months
Adverse Events
Duration of Response (DOR)
Objective Response Rate (ORR)
Overall Survival (OS)
Progression-free Survival (PFS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Cohort B: PD-L1 TPS≥ 1%
1 of 2
Cohort A: PD-L1 TPS≥ 1%
1 of 2

Experimental Treatment

90 Total Participants · 2 Treatment Groups

Primary Treatment: Cohort B: PD-L1 TPS≥ 1% · No Placebo Group · Phase 2

Cohort B: PD-L1 TPS≥ 1%Experimental Group · 2 Interventions: Adagrasib in combination with pembrolizumab, Pembrolizumab · Intervention Types: Drug, Biological
Cohort A: PD-L1 TPS≥ 1%Experimental Group · 2 Interventions: Adagrasib in combination with pembrolizumab, Pembrolizumab · Intervention Types: Drug, Biological
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
2017
Completed Phase 3
~2580

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 30 months

Who is running the clinical trial?

Mirati Therapeutics Inc.Lead Sponsor
58 Previous Clinical Trials
6,289 Total Patients Enrolled
2 Trials studying Advanced Non Small Cell Lung Cancer (NSCLC)
590 Patients Enrolled for Advanced Non Small Cell Lung Cancer (NSCLC)
Viola Chen, MDStudy DirectorMirati Therapeutics Inc.

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 25th, 2021

Last Reviewed: November 28th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.